Artios Pharma Ltd.
- Country
- π¬π§United Kingdom
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.artiospharma.com
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
- Conditions
- Metastatic Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 260
- Registration Number
- NCT05898399
- Locations
- πΊπΈ
Jefferson University Hospitals - Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈSCRI oncology partners, Nashville, Tennessee, United States
πΊπΈSouth Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids, Michigan, United States
Study of ART0380 in Patients With Biologically Selected Solid Tumors
- Conditions
- Metastatic CancerAdvanced Solid TumorRecurrent Endometrial Cancer
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT05798611
- Locations
- πΊπΈ
University of California Los Angeles (UCLA), Los Angeles, California, United States
πΊπΈThe University of Chicago, Chicago, Illinois, United States
πΊπΈDana Farber Cancer Center, Boston, Massachusetts, United States
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
- Conditions
- Advanced CancerBreast CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 390
- Registration Number
- NCT04991480
- Locations
- πΊπΈ
Yale School of Medicine, New Haven, Connecticut, United States
πΊπΈFlorida Cancer Specialists, Orlando, Florida, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
- Conditions
- Solid Tumor, Unspecified, Adult
- Interventions
- Other: Determination of ATM alteration status.
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 229
- Registration Number
- NCT04976803
- Locations
- π¬π§
Sarah Cannon Research UK, London, United Kingdom
πΊπΈOklahoma University, Oklahoma City, Oklahoma, United States
πΊπΈTennessee Oncology, Nashville, Tennessee, United States
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Conditions
- Fallopian Tube CancerAdvanced CancerMetastatic CancerOvarian CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 547
- Registration Number
- NCT04657068
- Locations
- πΊπΈ
Cancer Specialists of North Florida, Jacksonville, Florida, United States
πΊπΈMinnesota Oncology Hematology, Maple Grove, Minnesota, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States